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Abstract
Introduction: The Joint United Nations Programme on HIV/AIDS (UNAIDS) projections of paediatric HIV prevalence and
deaths rely on the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium for mortality estimates among
children living with HIV (CHIV) receiving antiretroviral therapy (ART). Previous estimates, based on data through 2014, may
no longer be accurate due to expanded paediatric HIV care and treatment eligibility, and the possibility of unreported deaths
in CHIV considered lost to follow-up (LTFU). We therefore estimated all-cause mortality and its trends in CHIV (<15 years
old) on ART using extended and new IeDEA data.
Methods: We analysed (i) IeDEA observational data from CHIV in routine care globally, and (ii) novel data from an IeDEA
tracing study that determined outcomes in a sample of CHIV after being LTFU in southern Africa. We included 45,711 CHIV
on ART during 2004 to 2017 at 72 programmes in Africa, Asia-Pacific and Latin America. We used mixed effects Poisson
regression to estimate mortality by age, sex, CD4 at ART start, time on ART, region and calendar year. For Africa, in an
adjusted analysis that accounts for unreported deaths among those LTFU, we first modified the routine data by simulating
mortality outcomes within six months after LTFU, based on a Gompertz survival model fitted to the tracing data (n = 221).
Results: Observed mortality rates were 1.8 (95% CI: 1.7 to 1.9) and 9.4 (6.3 to 13.4) deaths per 100 person-years in the
routine and tracing data, respectively. We found strong evidence of higher mortality at shorter ART durations, lower CD4
values, and in infancy. Averaging over covariate patterns, the adjusted mortality rate was 54% higher than the unadjusted
rate. In unadjusted analyses, mortality reduced by an average 60% and 73% from 2005 to 2017, within and outside of Africa,
respectively. In the adjusted analysis for Africa, this temporal reduction was 42%.
Conclusions: Mortality rates among CHIV have decreased substantially over time. However, when accounting for worse out-
comes among those LTFU, mortality estimates increased and temporal improvements were slightly reduced, suggesting cau-
tion in interpreting analyses based only on programme data. The improved and updated IeDEA estimates on mortality among
CHIV on ART support UNAIDS efforts to accurately model global HIV statistics.
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1 INTRODUCT ION
Accurate estimates of the number of children living with HIV
(CHIV) are essential for programme planning and resource
allocation [1,2]. Further, the number of deaths among CHIV
and paediatric antiretroviral therapy (ART) coverage are
important measures of programme effectiveness and progress
towards targets such as the Joint United Nations Programme
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on HIV/AIDS (UNAIDS) 90-90-90 goal [3]. In many countries,
these HIV statistics cannot be directly estimated, and we rely
on mathematical models to derive them.
The UNAIDS Spectrum model (Spectrum) [4] generates
robust global HIV estimates from country-specific service
statistics, survey and surveillance data, and epidemiological
parameters derived from scientific studies. Previously, Spec-
trum incorporated estimates of mortality among CHIV on ART
from the International epidemiology Databases to Evaluate
AIDS (IeDEA) consortium using data through 2014 [5].
However, paediatric HIV programmes have evolved over
time [6–9]. Improved prevention of mother-to-child transmis-
sion, early infant diagnosis and PCR testing at birth, as well as
earlier ART start and universal treatment, are likely to have
impacted mortality, previously modelled in Spectrum as con-
stant over time. Additionally, as the mortality estimates were
derived from routine treatment programme data, and did not
account for the possible under-ascertainment of mortality in
children recorded as lost to follow-up (LTFU), mortality may
have been underestimated [10].
In this study, we estimated all-cause mortality rates and
investigated their temporal trends among CHIV younger than
15 years on ART, during 2004 to 2017, in multiple regions
within and outside of Africa. Unique to this analysis are the
two distinct data sources: for all regions, we used routine-
care IeDEA observational data from participating treatment
programmes; for southern Africa, we additionally used novel
IeDEA data from a recent tracing study that determined out-
comes in a sample of CHIV considered LTFU [11,12]. The sec-
ond data source provided insights into deaths that are poten-
tially missed by programmes.
2 METHODS
2.1 Data sources
The IeDEA collaboration collects and harmonizes HIV/AIDS
data globally [13–16]. As of 2020, it had consolidated data on
approximately two million people living with HIV from partic-
ipating routine care treatment programmes, each comprised
of multiple centres. In this analysis, we included all routine
programmatic data (referred to as the “routine data,” below)
on CHIV younger than 15 years, who were receiving ART (a
combination of at least three antiretroviral drugs) initiated for
the first time between 2001 and 2017. Six IeDEA regions
contributed data: central Africa; East Africa; southern Africa;
West Africa; Asia-Pacific; and central America, South America
and the Caribbean (hereafter ‘Latin America’).
We also utilized data from a recent IeDEA tracing study in
six treatment programmes in five countries (Zambia, Malawi,
Zimbabwe, Lesotho and Mozambique) in southern Africa.
From the traced sample of 3256 persons classified as LTFU
by participating programmes [11,12], we used the subsample
of CHIV aged younger than 15 years, who had not visited
the clinic for at least the previous 120 to 180 days, depend-
ing on local definitions of LTFU. The children’s outcomes were
determined using phone calls and home visits. The sample was
identified and traced during 2017 to 2019, with last clinic vis-
its occurring during 2013 to 2017.
Within IeDEA [14], each participating programme has ethi-
cal approval from appropriate local institutions to collect and
share patient data. Each region’s data centre, which con-
solidates the data, has ethical approval to analyse the de-
identified data. At the time of ART initiation, CHIV or their
caregivers provided consent for being traced.
2.2 Analysis
Analyses were performed in R version 3.6.3 [17] and Stata
version 15.1 (Stata Corp., College Station, TX, USA). The anal-
ysis design was guided by Spectrum requirements [4,18] and
features of the data. We performed separate analyses for four
distinct data subsets—separating the four sub-Saharan African
regions from the remaining two regions (Asia-Pacific and Latin
America); and, within each group of regions, separating chil-
dren aged younger than five from those five to 14 years.
We performed two distinct analyses to produce: (i) “unad-
justed” estimates of mortality, based on the routine data only;
and (ii) for the African regions, “adjusted” estimates that incor-
porated the tracing study data. Secondary sensitivity analy-
ses were also performed to investigate the impact of selected
analysis decisions. All analyses are described below.
2.3 Unadjusted mortality rates
We analysed counts of deaths in the routine data using a
multivariable Poisson mixed effects regression model (log link
function). A child’s time at risk started at the later of pro-
gramme enrolment and ART initiation, and either ended at
death (if recorded before age 15) or was censored at the ear-
liest of turning 15 years old, being transferred to another pro-
gramme, and last being seen alive, based on recorded clinic,
laboratory and pharmacy visits. We excluded data beyond pro-
gramme’s centre-specific “database closure dates”, from which
we consider records incomplete.
Covariates included were consistent with how CHIV are
distinguished in Spectrum [4]. These were time-fixed sex and
CD4 at ART initiation, and time-varying time since ART ini-
tiation (<6 months, ≥6 months and <1 year, ≥1 year) and
current age (<1, 1 to 2, 3 to 4, 5 to 9, 10 to 14 years).
We included region as a covariate; and heterogeneity among
programmes was captured by a normally distributed random
effect.
To describe temporal trends in mortality, we included cal-
endar year as a linear spline with a single knot in 2010 (Web
Appendix E in Appendix S1 describes how the trend specifica-
tion was chosen).
For the CD4 at ART initiation covariate, CD4 percentage
measures were used in children younger than five years (<5,
5 to 10, 11 to 15, 16 to 20, 21 to 25, 26 to 30, >30%), and
CD4 counts in CHIV aged at least five years (≤200, 200 to
349, 350 to 499, 500 to 749, 750 to 999, ≥1000 cells/mm3).
From our IeDEA data, we extracted the CD4 measurement
closest to, and within six months before and two weeks after,
ART initiation. CD4 was modelled as pseudo-continuous, using
the (base 10) logarithm of the midpoint of the CD4 interval.
In Spectrum [18], when CHIV turn five years old, CD4 per-
centages are translated into CD4 counts using a transition
probability matrix [4]. Accordingly, we stochastically assigned
84
Kassanjee R et al. Journal of the International AIDS Society 2021, 24(S5):e25780
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25780/full | https://doi.org/10.1002/jia2.25780
CD4 count categories from a multinomial distribution using
the transition probabilities (see Web Appendix A in Appendix
S1) before analyzing the data. The simulation and analysis
were repeated five times, and Rubin’s rules [19] used to
combine results. CHIV with missing CD4 values (44%) were
excluded from the analysis, assuming that mortality outcomes
are missing at random given model covariates.
Informed by likelihood ratio (LR) tests, we allowed for dis-
tinct covariate effects by ART duration (less than vs. at least
one year), for each of CD4, region and the temporal trend.
2.4 Adjusted mortality rates
It is anticipated that a substantial number of child deaths
remain unrecorded in the routine data because ART pro-
grammes in Africa do not generally link patient records to
vital registration systems or use active follow-up [20]. The
adjusted mortality estimates attempt to account for these
unrecorded deaths, using the southern Africa tracing data.
The tracing data were used to adjust mortality for all sub-
Saharan African regions, assuming similarities in programmes
and patterns of ascertainment of mortality in these regions,
where most children receive care at public clinics following
generally comparable national guidelines. We did not attempt
to adjust estimates for Asia-Pacific and Latin America, where
children are more likely to receive care in specialized pae-
diatric facilities and patterns of mortality ascertainment are
likely to be different.
To generate adjusted mortality estimates, we applied an
approach similar to that used for adult on-ART mortality rate
inputs for Spectrum [20] (see Web Appendix B in Appendix
S1 for a graphic of our methods). To begin, for CHIV in the
routine data who were considered LTFU by the treatment
programmes, we simulated mortality outcomes over the six-
month period after becoming LTFU, based on a model deter-
mined from the tracing study data (the “simulation model”
below). Thereafter, the analysis proceeded similarly to the
unadjusted analysis above.
Consistent with the tracing study LTFU definitions, a child
was considered LTFU (at the date last seen alive) if neither
death nor transfer to another treatment programme were
recorded, and the child did not access care within the six
months preceding the centre database closure date. Simula-
tion was restricted to six months after LTFU as it becomes
increasingly uncertain whether a child remains on ART as
this horizon is extended. The simulation and analysis were
repeated 20 times, and results combined using Rubin’s rules
[19].
The simulation model was obtained by fitting a Gompertz
proportional-hazards survival model to the tracing study data,
though restricting the number of parameters due to the small
sample of 221 CHIV (see Web Appendix C in Appendix S1 for
technical details on the simulation model and its application).
Covariates included were sex, and, at the time of LTFU, time
since ART initiation and age. In the tracing study, records at
clinics were first examined and tracing only occurred if out-
comes remained unknown—a binary indicator of whether trac-
ing was required was also included. There was insufficient
data to include CD4 at ART start. Calendar year of LTFU
and time from LTFU to tracing were excluded based on LR
tests. Programme was included as a gamma-distributed ran-
dom effect. Observations with missing values for covariates or
outcomes (e.g., due to missing contact details) were excluded,
assuming mortality outcomes are missing at random given
model covariates (41% reduction in sample size).
The calendar years of LTFU in the routine data (2004 to
2017) were different from those in the tracing study (2013
to 2017). To reduce potential biases, the simulation model
assumed that the temporal trends in mortality fitted to the
unadjusted routine data also apply after LTFU (see Web
Appendix C in Appendix S1).
2.5 Sensitivity analysis
We report the impact on estimated mortality of each of (i)
simulating outcomes for 90 days or one year after LTFU,
rather than six months; (ii) not including a time trend in the
simulation model; (iii) moving all centre closure dates one year
earlier (in case records are incomplete from earlier than indi-
cated); and (iv) the multiple imputation of missing CD4 values.
3 RESULTS
3.1 Unadjusted analysis
Characteristics of the 45,711 CHIV in the routine data (after
any data exclusions) are summarized in Table 1 (see Web
Appendix D in Appendix S1 for disaggregation by region) and
observed mortality rates in Table 2. Most of the CHIV were
in African regions (92%), and primarily southern Africa (68%).
Annual ART initiations peaked in 2009. The aggregate mortal-
ity rate was 1.8 deaths per 100 person-years. Mortality rates
were similar by sex, but varied by region, and were higher in
children younger than five years and further in the past.
The fitted Poisson regression models are described in
Table 3 (CHIV younger than five years), Table 4 (CHIV five
to 14 years) and Table 5 (temporal trends). Associations
between covariates and mortality were comparable in African
and other regions. Within each region, there was substantial
variation in mortality among programmes. In both age groups,
there was strong evidence of lower mortality at longer ART
durations (85% to 99% lower mortality when on ART for at
least one year vs. less than six months) and higher CD4 at
ART start (35% to 81% reduction in mortality from the lowest
CD4 category to the next). Mortality was highest in infants
(five- to six-fold higher in children aged less than one year
vs. three to four years). There was some evidence of regional
differences within Africa. For CHIV younger than five years,
mortality was lowest in southern Africa (even after accounting
for this region’s greater interprogramme variability). In older
CHIV, regional differences varied more by ART duration, and
central and West Africa experienced the highest mortality for
shorter ART durations. From 2005 to each of 2010 and 2017,
mortality rates decreased by 11% to 44% and 33% to 90%,
respectively, depending on the group of regions, ages or ART
durations (see Web Appendix E in Appendix S1 for the esti-
mated model parameters). There was strong evidence that
mortality declined from 2005 to 2017 for all groups, except
among CHIV younger than five years on ART for at least one
year.
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Table 1. Description of CHIV on ART in routine data








Total 41,836 (100.0) 3875 (100.0) 45,711 (100.0)
Sex
Female 21,234 (50.8) 1878 (48.5) 23,112 (50.6)
Male 20,602 (49.2) 1997 (51.5) 22,599 (49.4)
Region
Central Africa 839 (2.0) 839 (1.8)
East Africa 6982 (16.7) 6982 (15.3)
Southern
Africa
31,012 (74.1) 31,012 (67.8)
West Africa 3003 (7.2) 3003 (6.6)
Asia-Pacific 3285 (84.8) 3285 (7.2)
Latin America 590 (15.2) 590 (1.3)
Age at ART start (whole years)
<1 5506 (13.2) 520 (13.4) 6026 (13.2)
1–2 7771 (18.6) 699 (18.0) 8470 (18.5)
3–4 4844 (11.6) 661 (17.1) 5505 (12.0)
5–9 13,535 (32.4) 1365 (35.2) 14,900 (32.6)
10–14 10,180 (24.3) 630 (16.3) 10,810 (23.6)
CD4% at ART start, among ART start age <5 years
<5 971 (5.4) 329 (17.5) 1300 (6.5)
5–10 3147 (17.4) 321 (17.1) 3468 (17.3)
11–15 4107 (22.7) 341 (18.1) 4448 (22.2)
16–20 3678 (20.3) 338 (18.0) 4016 (20.1)
21–25 2483 (13.7) 210 (11.2) 2693 (13.5)
25–30 1537 (8.5) 148 (7.9) 1685 (8.4)
>30 2198 (12.1) 193 (10.3) 2391 (12.0)
CD4 count at ART start (cells/mm3), among ART start age ≥5 years
<200 8708 (36.7) 1090 (54.6) 9798 (38.1)
200–349 5873 (24.8) 395 (19.8) 6268 (24.4)
350–499 3662 (15.4) 227 (11.4) 3889 (15.1)
500–749 2957 (12.5) 170 (8.5) 3127 (12.2)
750–999 1413 (6.0) 57 (2.9) 1470 (5.7)
≥1000 1102 (4.6) 56 (2.8) 1158 (4.5)
Year of ART starta
2001–2005 3612 (8.6) 229 (5.9) 3841 (8.4)
2006–2009 16,159 (38.6) 1880 (48.5) 18,039 (39.5)
2010–2012 12,863 (30.7) 1058 (27.3) 13,921 (30.5)
2013–2014 5511 (13.2) 449 (11.6) 5960 (13.0)
2015–2017 3691 (8.8) 259 (6.7) 3950 (8.6)
aBoundaries of intervals chosen to correspond to ART eligibility guidelines changes. Abbreviations: ART, antiretroviral therapy; CHIV, children
living with HIV.
3.2 Adjusted analysis
The 221 CHIV included in the tracing study data analysis, and
their mortality rates, are described in Table 6. The median
years from LTFU to tracing was 1.6 (quartile 1 to 3: 1.0 to
2.8). The aggregate mortality rate was 9.4 deaths per 100
person-years (95% CI: 6.3 to 13.4), much higher than in the
routine data and varying substantially by programme.
The survival model fitted to the tracing study data (the
basis of the simulation model, see Web Appendix C in
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Table 2. Observed mortality rates among CHIV on ART in routine data






deaths Estimate 95% CI
Total 158,736 2871 1.81 1.74, 1.88
Sex
Female 78,512 1370 1.74 1.65, 1.84
Male 80,223 1501 1.87 1.78, 1.97
Region
Central Africa 3398 70 2.06 1.61, 2.60
East Africa 23,731 570 2.40 2.21, 2.61
Southern
Africa
102,109 1554 1.52 1.45, 1.60
West Africa 11,028 380 3.45 3.11, 3.81
Asia-Pacific 16,345 240 1.47 1.29, 1.67
Latin America 2126 57 2.68 2.03, 3.47
Current age (whole years)
<5 37,306 1436 3.85 3.65, 4.05
5–14 121,430 1435 1.18 1.12, 1.24
Current yeara
2001–2005 2394 233 9.73 8.52, 11.07
2006–2009 37,344 1217 3.26 3.08, 3.45
2010–2012 54,279 868 1.60 1.49, 1.71
2013–2014 35,360 380 1.07 0.97, 1.19
2015–2017 29,359 173 0.59 0.50, 0.68
aBoundaries of intervals chosen to correspond to ART eligibility guidelines changes. Abbreviations: ART, antiretroviral therapy; CHIV, children
living with HIV.
Appendix S1) is presented in Table 7. Though uncertainties
were large, higher mortality was associated with shorter ART
durations (three-fold higher for ART durations less than one
month vs. greater than or equal to one year) and younger
age (mortality was double in CHIV aged less than one year
vs. greater than or equal to five years). Additionally, females
experienced half the mortality rate experienced by males, and
the need for tracing after examining records was associated
with six-fold higher mortality.
For African regions, among the 42,898 CHIV who con-
tributed data to the adjusted analysis, outcomes were sim-
ulated for the 25% identified as LTFU (see Web Appendix
F in Appendix S1 for the proportions and characteristics of
those LTFU). Those LFTU were equally split into males and
females, and about a third (34%) were lost within six months
of starting ART and two thirds (65%) were at least five years
old.
Unadjusted and adjusted mortality rates are compared in
Figures 1 and 2 (CHIV younger than and at least five years
old, respectively), by CD4 at ART start, for selected groups of
the CHIV and years. Weighting each combination of covari-
ate values and calendar year (2004 to 2017) equally, the
adjusted mortality rate was on average 54% higher than the
unadjusted rate (39% decrease to 4.3-fold increase across
covariate patterns). These relative increases were similar by
region, but were larger in more recent years, at higher CD4
values, for the older age group, and for the high-mortality
groups (as defined by age, ART duration and sex—see
Figures 1 and 2).
The associations between covariates and mortality were
similar to those in the unadjusted analysis (see Web Appen-
dices G and H in Appendix S1 for adjusted mortality rate
ratios and a comparison of fitted mortality rates), though
with some evidence of larger sex differences (females expe-
rienced 20% lower mortality than males), and an atten-
uated yet strong CD4 effect. Temporal trends were also
reduced, though still substantial; mortality in 2017 was 5% to
64% lower than in 2005, depending on age group and ART
duration.
3.3 Sensitivity analysis
The sensitivity analyses (see Web Appendix I in Appendix S1
for details) suggest that estimated adjusted mortality rates
are generally stable, relative to uncertainties, against the deci-
sions investigated about how to perform the adjustment for
unreported deaths. Estimated mortality rates changed by at
most 13%, averaging over covariate patterns. However, unad-
justed results were more sensitive to the imputation of CD4
values—while the largest average change was of similar mag-
nitude, there were some large changes for individual covariate
patterns.
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Table 3. Mortality rate ratios and inter-programme heterogeneity among CHIV on ART younger than five years, controlling for
temporal trends, based on multivariable analysis of unadjusted routine data
African regions Latin America and Asia-Pacific
ART duration <1 year ART duration ≥1 year ART duration <1 year ART duration ≥1 year










Male Ref Ref Ref Ref
Female 0.94 (0.84, 1.05) 0.280 0.94 (0.84, 1.05) 0.280 0.94 (0.66, 1.32) 0.706 0.94 (0.66, 1.32) 0.706
ART duration
<6 months Ref Ref Ref Ref
≥6 months
and <1 year
0.37 (0.31, 0.43) <0.001 0.34 (0.21, 0.54) <0.001
≥1 year 0.15 (0.06, 0.36) <0.001 0.04 (0.01, 0.29) 0.002
Current age (whole years)a
<1 5.67 (4.71, 6.82) <0.001 5.67 (4.71, 6.82) <0.001 4.79 (2.88, 7.99) <0.001 4.79 (2.88, 7.99) <0.001
1–2 2.24 (1.93, 2.60) <0.001 2.24 (1.93, 2.60) <0.001 1.75 (1.17, 2.61) 0.006 1.75 (1.17, 2.61) 0.006
3–4 Ref Ref Ref Ref
CD4 % at ART initiation (%)b
<5 Ref Ref Ref Ref
5–10 0.57 (0.52, 0.63) <0.001 0.65 (0.51, 0.83) <0.001 0.30 (0.24, 0.38) <0.001 0.50 (0.25, 0.99) 0.047
11–15 0.44 (0.38, 0.51) 0.53 (0.37, 0.76) 0.17 (0.12, 0.24) 0.36 (0.13, 0.99)
16–20 0.37 (0.31, 0.44) 0.47 (0.31, 0.71) 0.12 (0.08, 0.18) 0.29 (0.09, 0.99)
21–25 0.33 (0.27, 0.40) 0.42 (0.26, 0.68) 0.09 (0.06, 0.15) 0.25 (0.06, 0.98)
25–30 0.30 (0.24, 0.36) 0.39 (0.23, 0.66) 0.07 (0.04, 0.12) 0.22 (0.05, 0.98)




0.64 (0.25, 1.63) 0.347 0.55 (0.14, 2.20) 0.403
East Africa Ref Ref
Southern
Africa
0.56 (0.28, 1.13) 0.103 0.32 (0.15, 0.68) 0.003




0.99 (0.24, 4.03) 0.986 1.10 (0.15, 8.26) 0.926














0.66 (0.25, 1.75) 0.66 (0.25, 1.75)
aDoes not vary by ART duration by model design: the same estimates apply for ART <1 year and ART ≥1 year.
bIncluded as pseudo-continuous in the model, as a value of log10(2.5 + 5i) for the ith category.
cAlternative interpretation of random effect variance: the 20% of programmes with the highest mortality have mortality rates at least 4.3, 1.7
and 3.9 times those in the 20% of programmes with the lowest mortality for southern Africa, other African regions, and Latin America/Asia-
Pacific, respectively. Abbreviations: ART, antiretroviral therapy; CHIV, children living with HIV.
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Table 4. Mortality rate ratios and inter-programme heterogeneity among CHIV on ART at least five years old, controlling for
temporal trends, based on multivariable analysis of unadjusted routine data
African regions Latin America and Asia-Pacific
ART duration <1 year ART duration ≥1 year ART duration <1 year ART duration ≥1 year










Male Ref Ref Ref Ref
Female 0.97 (0.87, 1.08) 0.589 0.97 (0.87, 1.08) 0.589 0.87 (0.64, 1.19) 0.382 0.87 (0.64, 1.19) 0.38
ART duration
<6 months Ref Ref Ref Ref
≥6 months and
<1 year
0.33 (0.27, 0.39) <0.001 0.24 (0.14, 0.41) <0.001
≥1 year 0.07 (0.03, 0.19) <0.001 0.00 (0.00, 0.05) <0.001
Current age (whole years)a
5–9 Ref Ref Ref Ref
10–14 1.05 (0.94, 1.18) 0.393 1.05 (0.94, 1.18) 0.393 0.92 (0.65, 1.30) 0.632 0.92 (0.65, 1.30) 0.632
CD4 count at ART initiation (cells/mm3)b
<200 Ref Ref Ref Ref
200–349 0.43 (0.38, 0.48) <0.001 0.54 (0.48, 0.61) <0.001 0.19 (0.10, 0.35) <0.001 0.53 (0.36, 0.78) 0.001
350–499 0.30 (0.25, 0.35) 0.42 (0.35, 0.49) 0.09 (0.04, 0.23) 0.40 (0.23, 0.70)
500–749 0.22 (0.17, 0.27) 0.33 (0.27, 0.41) 0.05 (0.02, 0.15) 0.31 (0.16, 0.63)
750–999 0.16 (0.13, 0.21) 0.27 (0.21, 0.34) 0.03 (0.01, 0.11) 0.25 (0.11, 0.58)
≥1000 0.13 (0.10, 0.17) 0.23 (0.18, 0.30) 0.02 (0.00, 0.08) 0.22 (0.09, 0.55)
Region
Central Africa 2.03 (0.93, 4.41) 0.076 0.84 (0.36, 1.94) 0.677
East Africa Ref Ref
Southern Africa 1.08 (0.60, 1.95) 0.790 0.63 (0.35, 1.14) 0.126
West Africa 3.13 (1.56, 6.28) 0.001 1.72 (0.85, 3.49) 0.130
Asia-Pacific Ref Ref
Latin America 0.50 (0.15, 1.60) 0.242 1.57 (0.50, 4.97) 0.443














0.36 (0.09, 1.40) 0.36 (0.09, 1.40)
aDoes not vary by ART duration by model design: the same estimates apply for ART <1 year and ART ≥1 year.
bIncluded as pseudo-continuous in the model, as the base 10 logarithm of either the midpoint of the interval or 1125 for the last category.
cAlternative interpretation of random effect variance: the 20% of programmes with the highest mortality have mortality rates at least 3.5,
2.1 and 3.4 times those in the 20% of programmes with the lowest mortality, for southern/West Africa, other African regions, and Latin
America/Asia-Pacific, respectively. Abbreviations: ART, antiretroviral therapy; CHIV, children living with HIV.
4 D ISCUSS ION
In this analysis of routine IeDEA programmatic data on more
than 45,000 CHIV younger than 15 years on ART, we found
that mortality rates substantially decreased over time. Mor-
tality rates in 2017 were an average 60% and 73% lower
than in 2005, in and outside of Africa, respectively, after con-
trolling for individual characteristics, and with some varia-
tion by age, region and ART duration. However, our adjusted
analysis, using novel IeDEA tracing study data [11,12], sug-
gests that analyses using only routine programme data may
substantially underestimate mortality. The aggregate observed
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Table 5. Mortality rate ratios describing temporal trendsa among CHIV on ART (reference year 2005), controlling for sex, age,
ART duration, CD4 at ART start and region, based on multivariable analysis of unadjusted routine data
African regions Latin America and Asia-Pacific
ART duration <1 year ART duration ≥1 year ART duration <1 year ART duration ≥1 year
Age group Year Estimate (95% CI) p-Value Estimate (95% CI) p-Value Estimate (95% CI) p-Value Estimate (95% CI) p-Value
<5 years 2010 0.58 (0.48, 0.70) <0.001 0.86 (0.45, 1.66) 0.655 0.61 (0.43, 0.88) 0.007 0.66 (0.22, 2.00) 0.463
2017 0.21 (0.15, 0.30) <0.001 0.67 (0.34, 1.29) 0.229 0.31 (0.13, 0.73) 0.007 0.37 (0.03, 5.27) 0.463
≥5 years 2010 0.62 (0.48, 0.79) <0.001 0.66 (0.40, 1.09) 0.108 0.89 (0.43, 1.84) 0.758 0.56 (0.14, 2.21) 0.405
2017 0.23 (0.16, 0.35) <0.001 0.50 (0.31, 0.78) 0.002 0.30 (0.10, 0.91) 0.034 0.10 (0.03, 0.39) <0.001
aCalendar year is included in the regression model as a linear spline with knot at 2010. Abbreviations: ART, antiretroviral therapy; CHIV, chil-




























































































































2005                  2017                  2005                  2017
High−mortality group                          Low−mortality group
Figure 1. Model-fitted mortality rates (and 95% CIs as shaded areas) among CHIV on ART younger than five years, both unadjusted
using only the routine data (dashed black line) and adjusted by simulating outcomes for six months following LTFU (solid red line).
Deaths per 100 person-years (y-axis; log scale) are shown by CD4% at ART start (x-axis) for each of the four African regions (rows),
for 2005 and 2017 (columns) and for high- and low-mortality groups (columns) as defined by ART duration, age and sex (high: ART less
than six months, age less than one year, male; low: ART greater than or equal to one year, age three to four years, female). Mortality
rates are reported on a log scale to improve readability. ART, antiretroviral therapy; CHIV, children living with HIV.
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100 py (95% CI)
Total 221 (100.0) 30 319 9.4 (6.3, 13.4)
Sex
Female 120 (54.3) 11 174 6.3 (3.1, 11.3)
Male 101 (45.7) 19 144 13.2 (7.9, 20.5)
Programme
1 9 (4.1) 0 14 0.0 (0.0, 26.2)
2 92 (41.6) 10 143 7.0 (3.4, 12.9)
3 19 (8.6) 2 28 7.2 (0.9, 26.0)
4 46 (20.8) 11 45 24.7 (12.3, 44.2)
5 29 (13.1) 2 51 3.9 (0.5, 14.2)
6 26 (11.8) 5 39 12.8 (4.2, 29.9)
Age at LTFU (whole years)
<1 15 (6.8) 5 21 24.3 (7.9, 56.7)
1–2 58 (26.2) 9 86 10.5 (4.8, 19.9)
3–4 40 (18.1) 5 57 8.7 (2.8, 20.3)
5–14 108 (48.9) 11 155 7.1 (3.5, 12.7)
ART duration at LTFU
<1 montha 29 (13.1) 8 42 18.9 (8.2, 37.3)
≥1 and
<6 months
53 (24.0) 8 79 10.1 (4.4, 20.0)
≥6 months
and <1 year
49 (22.2) 7 72 9.8 (3.9, 20.1)
≥1 year 90 (40.7) 7 126 5.5 (2.2, 11.4)
Year of LTFU
2013 3 (1.4) 0 6 0.0 (0.0, 66.9)
2014 45 (20.4) 8 71 11.2 (4.8, 22.1)
2015 38 (17.2) 4 64 6.2 (1.7, 16.0)
2016 89 (40.3) 11 136 8.1 (4.0, 14.4)
2017 46 (20.8) 7 42 16.8 (6.7, 34.5)
Time from LTFU to tracing (whole years)
0 49 (22.2) 6 43 13.8 (5.1, 30.0)
1 83 (37.6) 13 127 10.2 (5.4, 17.5)
2 39 (17.6) 3 67 4.4 (0.9, 13.0)
3 or 4 50 (22.6) 8 81 9.9 (4.3, 19.5)
Tracing required
No 51 (23.1) 2 68 2.9 (0.4, 10.6)
Yes 170 (76.9) 28 251 11.2 (7.4, 16.1)
aAn additional ART duration category (compared to the routine data analysis) is included to account for stratified sampling in the tracing study.
Abbreviations: ART, antiretroviral therapy; CHIV, children living with HIV.
mortality rate in the southern Africa tracing study, which
considered CHIV after LTFU, was five times greater than
among CHIV recorded as in care by treatment programmes
in the same region or globally (9.4 vs. 1.5 or 1.8 deaths
per 100 person-years, respectively). For African regions, the
detailed analysis that adjusted for unreported deaths resulted
in an average 54% increase in estimated mortality rates and
a dampening of the temporal trend; mortality in 2017 was
42% lower than in 2005. These analyses produced mortal-
ity inputs for the UNAIDS Spectrum model that are signifi-
cantly improved and updated, supporting more accurate mod-
elling of global HIV statistics for the purposes of resource
allocation.
Our study concurs with several previous analyses [21–23]:
high mortality rates were associated with short ART dura-
tions, low CD4 values at ART start, and infancy. There was
some variation by region, and, within each region, there was
notable interprogramme variability, highlighting the need to
incorporate this heterogeneity into mortality estimates while
striving towards more equitable care. The temporal reductions
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High−mortality group                          Low−mortality group
Figure 2. Model-fitted mortality rates (and 95% CIs as shaded areas) among CHIV on ART at least five years old, both unadjusted when
using only the routine data (dashed black line) and adjusted by simulating outcomes for six months following LTFU (solid red line).
Deaths per 100 person-years (y-axis; log scale) are shown by CD4 count at ART start (x-axis) for each of the four African regions (rows),
for 2005 and 2017 (columns) and for high- and low-mortality groups (columns) as defined by ART duration, age and sex (high: ART less
than six months, age 10 to 14 years, male; low: ART greater than or equal to one year, age five to nine years, female). Mortality rates
are reported on a log scale to improve readability. ART, antiretroviral therapy; CHIV, children living with HIV.
in mortality estimates in our and other studies [24] suggest
that guideline and programme implementation changes have
improved child outcomes. This underscores the need to reg-
ularly update parameters used in HIV models.
It is recognized that retention in programmes remains a
challenge in Africa [25,26], thus, a key limitation to the accu-
rate estimation of mortality rates from data collected by treat-
ment programmes is the possibly different but unobserved
mortality in those considered LTFU. Reasons for LTFU are
diverse, including that some patients are in fact still partic-
ipating in the same or another programme, but records do
not accurately reflect this [11]. Importantly, some deaths may
not be recorded in CHIV who are mistakenly considered LTFU
[27,28]. To our knowledge, the tracing data used in this analy-
sis is from the first such study of more than 100 CHIV chil-
dren on ART [29,30], and the substantially higher mortality
seen in children LTFU underscores the importance of con-
ducting such studies to accurately assess outcomes and re-
engage individuals in care, efficient and effective methods of
tracing, and improved record keeping to reduce misclassifica-
tion as LTFU.
The relative adjustments in mortality rates, from incorpo-
rating the tracing data, are larger in more recent years and
among older children. Some of the increasing adjustment with
time may be explained by increasing rates of LTFU—the pro-
portion of CHIV contributing data each calendar year, who
are also LTFU in that year, grew from 4% in 2005 to 8%
in 2016. While the factors associated with mortality in CHIV
after LTFU were generally consistent with those found in the
routine data, mortality after being LTFU was strongly asso-
ciated with being male. This translated into higher mortality
among males in the adjusted analysis of the routine data, high-
lighting that, as with older men, boys may be at greater risk of
poorer outcomes [31,32].
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Table 7. Mortality rate ratios and model parameters for CHIV
on ART after they are LTFU, based on multivariable analysis
of tracing study data
Mortality rate ratio
Estimate (95% CI) p-Value
Sex
Male Ref
Female 0.47 (0.22, 1.04) 0.062
ART duration
<1 montha 3.33 (1.04, 10.67) 0.042
≥1 and <6 months 1.31 (0.43, 3.99) 0.630
≥6 months and <1 year 1.34 (0.43, 4.16) 0.616
≥1 year Ref
Current age (whole years)
<1 2.22 (0.68, 7.25) 0.188
1–2 1.22 (0.47, 3.18) 0.677




Yes 6.14 (1.38, 27.25) 0.017
Parameter estimate
Estimate (95% CI) p-Value
Random effect variancec,d 0.38 (0.05, 2.63) 0.325
Gompertz ancillary parameterc −1.84 (−2.76, −0.92) <0.001
aAn additional ART duration category (compared to the routine data
analysis) is included to account for stratified sampling in the tracing
study
bCategories are collapsed (compared to the routine data analysis)
due to the small sample.
cSee Web Appendix B in Appendix S1 for the full model form speci-
fication.
dAlternative interpretation of random effect variance: the 20% of
programmes with the highest mortality have mortality rates at least
3.0 times those in the 20% of programmes with the lowest mortality.
Abbreviations: ART, antiretroviral therapy; CHIV, children living with
HIV.
Many studies that estimate mortality from routine pro-
gramme data treat LTFU as either non-informative or use
methods such as complete-case analysis or multiple imputa-
tion, which often rely on assumptions leading to biases [10].
When outcomes are known in a subsample of those LTFU,
determined through tracing studies or linkage to registries,
inverse probability weighting can provide a practical approach
to analyses [10]. However, in this analysis, we used a simula-
tion approach [10,20,27] as outcomes were known for only a
small sample of CHIV who were LFTU.
Limitations of this study include that IeDEA treatment
programmes may not be representative of their region,
though inclusion of multiple programmes and the use of
random effects in analyses to describe heterogeneity miti-
gates this concern. Further limitations are the small sample
(n = 221) of CHIV LTFU from the southern African region
used to adjust mortality estimates for unreported deaths
in all sub-Saharan African regions, and the assumption that
fitted temporal trends in mortality before LTFU hold after
LTFU, incorporated without accounting for uncertainty. Other
researchers have cautioned against generalizing programme-
specific results [30,33]; and future updates of these mortality
estimates would benefit from a larger dataset on outcomes in
those LTFU, spanning additional years and regions. The large
number of missing outcomes in the tracing study may have
also introduced bias and highlights a remaining knowledge gap
about those not successfully traced. Further studies within
IeDEA are planned to determine outcomes either by tracing
or linkage to death registries [33]; for example, the IeDEA
central African region is initiating the first of its planned stud-
ies in Rwanda in 2021.
We did not attempt to adjust mortality estimates for
regions outside of Africa due to the absence of tracing study
data for these regions. While associations between covariates
and mortality were comparable in African and other regions,
we are limited in our ability to directly compare regions’ mor-
tality rates. While it may be argued that the likelihood of
unascertained mortality might be lower in Latin America and
Asia-Pacific regions [22,34], we may be underestimating mor-
tality by not applying any adjustments for potentially missed
deaths in our analysis of these regions. Within African regions,
by basing all adjustments on outcomes in a sample of those
LTFU in southern Africa, which has relatively low mortality
rates before LTFU, we may be under-adjusting mortality in the
other African regions. Even without these complexities, as we
estimate all-cause mortality in this study, many region-specific
factors not directly related to HIV could be contributing to
any differences observed in mortality.
The absence of usable CD4 data in the tracing study data
analysis, and thus omission of CD4 in the model used to sim-
ulate outcomes after LTFU, created caveats when interpret-
ing results. For some covariate patterns, the adjustment for
missed deaths resulted in a reduction of mortality, mainly at
lower CD4 values; as CD4 could not be included in the sim-
ulation, we expect an under- and over-estimation of adjusted
mortality at smaller and larger CD4 values, respectively. The
omission of CD4 is also likely to have increased the damp-
ening of temporal trends, as the CD4 distribution has shifted
upwards in recent years. The large amount of missing CD4
data in the routine data also posed challenges, as highlighted
by the sensitivity of our results to alternative missingness
assumptions. The increasing missingness of CD4 data raises
questions about whether HIV models should be adapted to
rely less on data no longer required to determine ART eligibil-
ity, or alternatively, whether the continued value of such data
is being under-emphasized for analysis and individual patient
care purposes.
5 CONCLUS IONS
In this first analysis of mortality among CHIV on ART incor-
porating tracing data, we have demonstrated a substantial
increase in mortality rate estimates for African regions upon
adjusting for mortality in those classified as LTFU, which has
important implications for interpreting reported mortality esti-
mates from routine care settings. The substantial temporal
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improvements in mortality outcomes among CHIV on ART
across our global cohorts are nevertheless reassuring, and
highlight the need to further enhance efforts at ensuring early
access to diagnosis and treatment, as well as retention in care,
to optimize outcomes for CHIV.
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